miltuximab-IRDye800CW

Miltuximab-IRDye800CW is a **conjugate of the chimeric monoclonal antibody Miltuximab (targeting Glypican-1, GPC-1) with the near-infrared fluorescent dye IRDye800CW**. It is designed for **molecular imaging, notably intraoperative fluorescence-guided visualization of tumors that overexpress GPC-1, such as glioblastoma and urothelial carcinoma**. The agent binds specifically to GPC-1-expressing tumor tissues and accumulates in these lesions, enabling real-time imaging during surgery and potentially improving the completeness of tumor resection. The specificity comes from the antibody's high affinity for GPC-1, which is overexpressed in certain malignancies but not in most normal tissues. After intravenous administration, the conjugate retains both target binding and fluorescence, demonstrating high tumor-to-background ratios persistently for days post-injection in preclinical mouse models.

Brand names

Miltuximab-IRDye800CWMiltuximab-IRDye-800CWMiltuximab-IRDye 800CW

Other names

Miltuximab-IR800Miltuximab-IR-800Miltuximab-IR 800Miltuximab-IR800CWMiltuximab-IR-800CWMiltuximab-IR 800CW